Editorial

Dr. Md. Mezbahul Alam

Hope and Constraints of the high-tech frontier versus the enduring vitality of optical devices

The era of regenerative medicine has arrived, marked by significant milestones in 2025. Treatments like Luxturna (Gene therapy) and emerging CRISPR-based "gene surgeries" are now targeting inherited retinal diseases (IRDs) such as retinitis pigmentosa. Second-generation suprachoroidal retinal prostheses (Bionic eye) and photovoltaic subretinal implants (such as the PRIMA system) have demonstrated "substantial improvements" in functional vision, allowing patients to detect obstacles and navigate independently. Despite these advances, these technologies face steep hurdles, including extreme costs (e.g., historical costs exceeding $145,000 for early models), limited resolution that does not yet restore "normal" vision, and restricted eligibility based on specific genetic profiles.

In 2025, optical devices are not obsolete; they are evolving alongside high-tech interventions. The low vision aids market is projected to reach $3.32 billion in 2025, growing at over 10% annually, driven by immediate accessibility, technological integration, and device personalization.

Unlike surgery or therapy, optical devices like bioptic telescopes, high-powered magnifiers, and specialized filters provide immediate functional gains without the risks of invasive procedures.

Traditional aids are being "smartened." Wearable digital magnifiers (e.g., IrisVision, Jordy) now utilize AI for real-time text-to-speech, object recognition, and high-definition image enhancement. Low-vision optometrists in 2025 emphasize that no single device fits all; expert guidance is required to match tools to a patient's specific remaining vision and lifestyle goals.

The "cure" versus "aid" debate is shifting toward a hybrid model of care to Bridge the gap. For many patients receiving gene therapy or bionic implants, vision may be partially restored (e.g., light perception or silhouettes). Optical aids remain necessary to bridge the gap between "detecting shapes" and "reading fine print". Advances in augmented reality (AR) and AI-powered smart glasses are creating a new category of "hybrid" devices that blend traditional optical magnification with digital processing, making vision care more inclusive and adaptive.

In conclusion, while 2025 marks a turning point for curative therapies, the low vision optical device remains an indispensable tool. The future of vision care lies not in choosing one over the other, but in a synergistic approach that maximizes a patient's functional independence through every available means.

Dr. Md. Mezbahul Alam
Associate Professor,
National Institute of Ophthalmology & Hospital